S. C. Schimpff
Impact in
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Antibiotics Pharmacokinetics and Efficacy 7
- Oncology 6
- Neutropenia and Cancer Infections 5
- Co-authors
- George L. Drusano (5 shared papers)P. H. Wiernik (3 shared papers)Carlos A. De Jongh (2 shared papers)Harold C. Standiford (4 shared papers)Kathryn A. Newman (2 shared papers)William L. Hewitt (1 shared paper)James C. Wade (1 shared paper)John Crowley (1 shared paper)
- Journals
- Clinical Infectious Diseases (3 papers)The Lancet (3 papers)Infection (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)Melanoma Research (1 paper)
- Partner nations
- United StatesMalaysiaUnited Kingdom
In The Last Decade
S. C. Schimpff
18 papers receiving 428 citations
Peers
Comparison fields: 5 of 74
- Molecular Medicine 115
- Applied Microbiology and Biotechnology 21
- Clinical Biochemistry 71
- Pharmacology 162
- Critical Care and Intensive Care Medicine 34
Countries citing papers authored by S. C. Schimpff
This map shows the geographic impact of S. C. Schimpff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. C. Schimpff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. C. Schimpff more than expected).
Fields of papers citing papers by S. C. Schimpff
This network shows the impact of papers produced by S. C. Schimpff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. C. Schimpff. The network helps show where S. C. Schimpff may publish in the future.
Co-authors
The 25 scholars most cited alongside S. C. Schimpff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1983 | 84 | |
| 2 | 1972 | 73 | |
| 3 | 1984 | 70 | |
| 4 | 1984 | 48 | |
| 5 | 1984 | 40 | |
| 6 | Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. | 1976 | 39 |
| 7 | 1975 | 34 | |
| 8 | 1982 | 25 | |
| 9 | 1979 | 18 | |
| 10 | 1984 | 14 | |
| 11 | 1995 | 14 | |
| 12 | 1985 | 10 | |
| 13 | 1987 | 8 | |
| 14 | 1982 | 7 | |
| 15 | Antibiotic combinations for the empiric treatment of the febrile neutropenic patient. | 1983 | 6 |
| 16 | 1978 | 3 | |
| 17 | 1973 | 3 | |
| 18 | 1993 | 2 |
About S. C. Schimpff
S. C. Schimpff is a scholar working on Pharmacology, Oncology, Infectious Diseases, Epidemiology and Public Health, Environmental and Occupational Health, having authored 18 papers that have together received 498 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (7 papers), Neutropenia and Cancer Infections (5 papers), Antibiotic Resistance in Bacteria (3 papers), Amoebic Infections and Treatments (2 papers), Acute Lymphoblastic Leukemia research (2 papers), Analytical Methods in Pharmaceuticals (2 papers), Antimicrobial Resistance in Staphylococcus (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Molecular Medicine (115 citations), Applied Microbiology and Biotechnology (21 citations), Clinical Biochemistry (71 citations), Pharmacology (162 citations) and Critical Care and Intensive Care Medicine (34 citations). S. C. Schimpff has collaborated with scholars based in United States, Malaysia and United Kingdom. Frequent co-authors include George L. Drusano, P. H. Wiernik, Carlos A. De Jongh, Harold C. Standiford, Kathryn A. Newman, William L. Hewitt, James C. Wade, John Crowley, Marcia R. Moody and Beverly A. Tatem. Their work appears in journals such as Clinical Infectious Diseases, The Lancet, Infection, Antimicrobial Agents and Chemotherapy and Melanoma Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.